Obesity as an aggravating factor of systemic lupus erythematosus disease: What we already know and what we must explore? - A rapid scoping review

被引:1
|
作者
Carvalho, Lucas M. [1 ,2 ,3 ]
Carvalho, Beatriz G. [1 ,2 ,3 ]
Souza, Leticia L. [1 ,2 ,3 ]
da Mota, Jhulia C. N. L. [1 ,2 ,3 ]
Ribeiro, Amanda A. [1 ,2 ,3 ]
Nicoletti, Carolina F. [1 ,2 ,3 ,4 ]
机构
[1] Univ Sao Paulo, Sch Phys Educ & Sport, Appl Physiol & Nutr Res Grp, Sao Paulo, Brazil
[2] Univ Sao Paulo, Fac Med FMUSP, Sao Paulo, Brazil
[3] Univ Sao Paulo, Fac Med FMUSP, Ctr Lifestyle Med, Sao Paulo, Brazil
[4] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Rheumatol Div, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
Systemic lupus erythematosus; Obesity; Adipose tissue; Inflammation; Eating disorders; Microbiota; QUALITY-OF-LIFE; BODY-MASS INDEX; FUNCTIONAL-CAPACITY; CARDIOVASCULAR RISK; EATING-DISORDERS; GUT MICROBIOTA; T-CELLS; IMPACT; HEALTH; INFLAMMATION;
D O I
10.1016/j.nut.2024.112559
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect various organs and systems. Symptoms of SLE can vary widely from person to person and over time, including fatigue, joint pain, skin rashes, fever, and inflammation of multiple organs. The association between SLE and excess body weight has been the subject of study, with evidence suggesting that overweight and obesity can worsen the disease's clinical presentation. Obesity is linked to a state of low-grade chronic inflammation, which can exacerbate the inflammation present in SLE. Additionally, obesity may negatively impact treatment response, disease progression, and patient prognosis. Patients with SLE and obesity may face additional challenges in managing the disease, such as increased symptom severity, higher risk of cardiovascular and renal complications, and a reduced response to conventional treatments. Obesity can also influence the quality of life of patients with SLE, making a holistic approach that considers the individual's nutritional status essential. Therefore, understanding the relationship between obesity and SLE is crucial for optimizing treatment, improving clinical outcomes, and enhancing patients' quality of life. Further research is needed to elucidate the underlying pathophysiological mechanisms, develop more precise and personalized management strategies, and identify biomarkers that can predict disease prognosis and treatment response. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:10
相关论文
共 49 条
  • [31] What we truly know about occupation as a risk factor for ALS: A critical and systematic review
    Sutedja, Nadia A.
    Fischer, Kathelijn
    Veldink, Jan H.
    van der Heijden, Geert J. M. G.
    Kromhout, Hans
    Heederik, Dick
    Huisman, Mark H. B.
    Wokke, John J. H.
    van den Berg, Leonard H.
    AMYOTROPHIC LATERAL SCLEROSIS, 2009, 10 (5-6): : 295 - U70
  • [32] What can we learn from the presence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus?
    Zhao, Yi
    Li, Jing
    Li, Xiao-xia
    Li, Chun
    Li, Lin
    Li, Zhan-guo
    JOINT BONE SPINE, 2009, 76 (05) : 501 - 507
  • [33] Epigenetic Variability in Systemic Lupus Erythematosus: What We Learned from Genome-Wide DNA Methylation Studies
    Teruel, Maria
    Sawalha, Amr H.
    CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (06)
  • [34] Epigenetic Variability in Systemic Lupus Erythematosus: What We Learned from Genome-Wide DNA Methylation Studies
    Maria Teruel
    Amr H. Sawalha
    Current Rheumatology Reports, 2017, 19
  • [35] What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials
    King, Kathryn
    McGuinness, Serena
    Watson, Natalie
    Norton, Christine
    Chalder, Trudie
    Czuber-Dochan, Wladyslawa
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 3265 - 3303
  • [36] Depression as a risk factor for Alzheimer's disease: Genes, steroids, cytokines and neurogenesis - What do we need to know?
    Herbert, Joe
    Lucassen, Paul J.
    FRONTIERS IN NEUROENDOCRINOLOGY, 2016, 41 : 153 - 171
  • [37] The mycobiota-gut-brain axis in Parkinson's disease: A review on what we know and what paths we can still take to advance this field of study
    Neto, Dionisio P. A. M. O. R. I. M.
    Sant'ana, Anderson S.
    FUNGAL BIOLOGY REVIEWS, 2023, 46
  • [38] What do we know about the psychosocial issues associated with cancer during pregnancy? A scoping review and gap analysis
    Harris, Jenny
    Ream, Emma
    Armes, Jo
    Gibson, Faith
    Marcu, Afrodita
    Parsons, Catherine Treena
    Robinson, Ann
    Varghese, Sherin
    Poole, Karen
    BMJ OPEN, 2023, 13 (03):
  • [39] What Do We Know After Decades of Research About Parenting and IPV? A Systematic Scoping Review Integrating Findings
    Sousa, Cindy A.
    Siddiqi, Manahil
    Bogue, Briana
    TRAUMA VIOLENCE & ABUSE, 2022, 23 (05) : 1629 - 1642
  • [40] What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE
    Lee, H. S.
    Bae, S-C
    LUPUS, 2010, 19 (12) : 1452 - 1459